Subtype
Hepatopancreatobiliary Carcinoma
CI-CAN-00002859Explore in graph →
1,360 active trials21 approved drugs69 evidence items
- NCIt
- C214986
Loading cancer entity…
Subtype
CI-CAN-00002859Explore in graph →
Clinical trials
5,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (645)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02585479 | Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Guangxi Medical UniversityOTHER | 0 | Jun 4, 2019 | clinicaltrials |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma(SEARCH) | completed | Phase 3 | 732 | BayerINDUSTRY | 26 | May 30, 2019 | clinicaltrials |
| NCT01470443 | Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma | unknown | Phase 3 | 240 | Samsung Medical CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT03939845 | A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi | unknown | Phase 3 | 180 | Shanghai Zhongshan HospitalOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03744247 | Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT03791918 | Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria | withdrawn | Phase 3 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT01676194 | Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma(CATCH) | terminated | Phase 3 | 7 | Rennes University HospitalOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT01229839 | Chemoembolization With or Without Mixing the Chemotherapy With Lipiodol for Unresectable HCC | completed | Phase 3 | 668 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01259414 | Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma | completed | Phase 3 | 812 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT02232490 | Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L(Hepko-V5) | unknown | Phase 3 | 120 | Immunitor LLCINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03313596 | Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC | unknown | Phase 3 | 180 | Huazhong University of Science and TechnologyOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT02220088 | The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial | terminated | Phase 2 / Phase 3 | 79 | Sun Yat-sen UniversityOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03775395 | HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC | unknown | Phase 3 | 250 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03779035 | Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection(AdBTC-1) | unknown | Phase 3 | 460 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03636620 | TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial(TACE+RFA) | completed | Phase 3 | 110 | Fudan UniversityOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT03469479 | Neoadjuvant HAIC for Resectable Hepatocellular Carcinoma Beyond Milan Criteria | unknown | Phase 3 | 252 | Sun Yat-sen UniversityOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT03551444 | Recurrence Rate of Hepatocellular Carcinoma After Treatment of Chronic Hepatits C Patients With Direct Acting Antivirals: Randomized Controlled Phase 3 Trial(CAUTIOUS) | unknown | Phase 3 | 80 | Ain Shams UniversityOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT01681446 | Adjuvant IFN-α for Patients Underwent Curative Surgery for HCC With a Low miR-26 Expression | unknown | Phase 3 | 296 | Fudan UniversityOTHER | 1 | Jun 1, 2018 | clinicaltrials |
| NCT03516448 | Expanding Phase III Study of Tyroserleutide for Injection | unknown | Phase 3 | 352 | Shenzhen Kangzhe Pharmaceutical Co., Ltd.INDUSTRY | 0 | May 4, 2018 | clinicaltrials |
| NCT01135056 | Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)(SIRveNIB) | unknown | Phase 3 | 360 | Singapore General HospitalOTHER | 12 | Apr 24, 2018 | clinicaltrials |
| NCT02149771 | Combination Treatment for Advanced Liver Cancer | withdrawn | Phase 3 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 19, 2018 | clinicaltrials |
| NCT01829035 | A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC | completed | Phase 3 | 339 | National Cancer Center, KoreaOTHER_GOV | 1 | Mar 29, 2018 | clinicaltrials |
| NCT03468231 | HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC | unknown | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Mar 16, 2018 | clinicaltrials |
| NCT03081039 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma | withdrawn | Phase 3 | 0 | University of LouisvilleOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT03345303 | Bortezomib in Intrahepatic Cholangiocellular Carcinoma | unknown | Phase 3 | 50 | Zhengang YuanOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01265810 | Caphosol in Oral Mucositis Due to Targeted Therapy(COMTT) | completed | Phase 3 | 64 | Impaqtt FoundationOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT03317886 | Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer | unknown | Phase 3 | 354 | Wakayama Medical UniversityOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT01901692 | Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion(START) | completed | Phase 2 / Phase 3 | 90 | Asan Medical CenterOTHER | 1 | Sep 18, 2017 | clinicaltrials |
| NCT03251365 | Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 42 | Hospital General de Ciudad RealOTHER | 1 | Aug 16, 2017 | clinicaltrials |
| NCT02767375 | Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection(HAICAT) | unknown | Phase 2 / Phase 3 | 192 | Peking University Cancer Hospital & InstituteOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT02482454 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma | active not recruiting | Phase 2 / Phase 3 | 50 | The First People's Hospital of ChangzhouOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00759109 | Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085) | completed | Phase 3 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 7, 2017 | clinicaltrials |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | terminated | Phase 3 | 35 | National Cancer Institute, NaplesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01869088 | TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma | unknown | Phase 3 | 266 | Sun Yat-sen UniversityOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT01804829 | Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients. | completed | Phase 3 | 80 | Biotest Pharmaceuticals CorporationINDUSTRY | 1 | Mar 15, 2017 | clinicaltrials |
| NCT01755013 | Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma | unknown | Phase 2 / Phase 3 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 20, 2017 | clinicaltrials |
| NCT01482442 | SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma(SARAH) | completed | Phase 3 | 496 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 16, 2017 | clinicaltrials |
| NCT02319200 | Primary Prevention Hepatocellular Carcinoma by Metformin(METFOVIR) | terminated | Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT01966133 | TACE as an Adjuvant Therapy After Hepatectomy for HCC | unknown | Phase 3 | 280 | Jia FanOTHER | 1 | Jan 9, 2017 | clinicaltrials |
| NCT02738697 | Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection | unknown | Phase 3 | 290 | Sun Yat-sen UniversityOTHER | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02630108 | TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma | unknown | Phase 3 | 280 | Shanghai Zhongshan HospitalOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT01360853 | Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer(ONTRAC) | completed | Phase 3 | 160 | Traws Pharma, Inc.INDUSTRY | 5 | Aug 4, 2016 | clinicaltrials |
| NCT02788526 | Adjuvant TACE to Reduce the HCC Recurrence After Resection | completed | Phase 3 | 180 | Sun Yat-sen UniversityOTHER | 1 | Jun 20, 2016 | clinicaltrials |
| NCT01964001 | The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer | completed | Phase 2 / Phase 3 | 71 | Taichung Veterans General HospitalOTHER | 1 | Jun 15, 2016 | clinicaltrials |
| NCT02755311 | Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma | unknown | Phase 3 | 198 | Sun Yat-sen UniversityOTHER | 1 | Apr 28, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jun 4, 2019source: clinicaltrials